What is the recommended BPC-157 dosage?

BPC-157 dosing varies by experience level. Beginners typically start at 250mcg 2x daily, moderate users at 500mcg daily, and aggressive protocols use 750mcg 2x daily.

How do you reconstitute BPC-157?

BPC-157 typically comes in 5mg or 10mg vials. Add 2mL of bacteriostatic water to the vial. Use our free calculator for exact syringe units based on your desired dose.

What is the half-life of BPC-157?

The half-life of BPC-157 is ~30 min plasma (functional tissue activity ~4 hours). This determines how frequently you need to dose for consistent blood levels.

BPC-157

Q: What are the side effects of BPC-157?

Very well-tolerated in research. Occasional mild nausea. No significant side effects reported in studies.

Healing & RecoveryInjection/OralPreclinicalGrade A~30 min plasma (functional tissue activity ~4 hours) half-life

Tissue RepairGut HealthNeuroprotectionAnti-Inflammatory6 weeks on / 2 weeks off

Benefits

Accelerates tendon, ligament, and muscle repair

Heals gut lining (leaky gut, IBS, ulcers)

Promotes new blood vessel formation

Neuroprotective properties

Works both orally and by injection

Half-Life

~30 min plasma

Route

Injection / Oral

Frequency

2x Daily

Vial Sizes

5mg, 10mg

BAC Water

2mL

Safety Grade

Grade A

Open BPC-157 Dosage Calculator

Calculate exact syringe units for your vial and dose

About BPC-157

BPC-157 (Body Protection Compound) is a 15-amino-acid peptide derived from a protein found in gastric juice. It accelerates healing of tendons, ligaments, muscles, nerves, and the gut lining. Research shows it promotes angiogenesis (new blood vessel formation), modulates nitric oxide, and upregulates growth factor receptors. It's stable in stomach acid, making it effective both orally and by injection.

Who Should Consider BPC-157

Athletes recovering from tendon, ligament, or muscle injuries
Individuals with gut issues (leaky gut, IBS, NSAID-induced damage)
Post-surgical patients seeking accelerated wound healing
People with chronic joint or connective tissue pain
Individuals recovering from nerve injuries

How BPC-157 Works

BPC-157 promotes healing through multiple pathways: it stimulates angiogenesis (new blood vessel formation) via VEGF upregulation, modulates nitric oxide synthesis, upregulates growth hormone receptors, and activates the FAK-paxillin pathway for tendon and ligament repair. It also has gastroprotective effects by promoting gastric mucosal integrity and counteracting NSAID damage.

What to Expect

Days 1-3

Peptide begins modulating nitric oxide and growth factor pathways. No visible changes yet. Reduced pain at injury site reported anecdotally.

Weeks 1-2

Early healing response underway. Reduced inflammation and pain around injury. Gut-related improvements (reduced bloating, discomfort) may begin.

Weeks 3-4

Noticeable improvement in tendon/ligament mobility and pain levels. Gut lining repair progressing. Angiogenesis supporting tissue remodeling.

Weeks 5-6

Significant functional recovery for most soft tissue injuries. Gut symptoms substantially improved. End of typical cycle — assess and consider a 2-week break before repeating.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	250mcg	2x Daily
Moderate	500mcg	Daily
Aggressive	750mcg	2x Daily

Note: Stable in gastric acid; oral and subcutaneous routes both researched. Inject close to injury site when possible. Commonly cycled 4-6 weeks on, 2 weeks off.

How to Inject BPC-157

For local injuries: inject subcutaneously as close to the injury site as possible for best results. For gut healing: oral administration is effective since BPC-157 is stable in stomach acid. Can also be injected subcutaneously into the abdomen for systemic effects.

Cycling Protocol

On Period

6 weeks

Off Period

2 weeks

Most users run 4-6 week cycles targeted at a specific injury. Can be repeated as needed after a brief break.

Pharmacokinetics

Half-Life

30min

Bioavailability

IM: ~14-19% (rats), ~45-51% (dogs); oral bioavailability not quantified but peptide is stable in gastric acid

Tmax

IM: <30 min (rats/dogs)

Data Confidence

low

Source: Animal PK data: t1/2 <30 min IV/IM in rats and dogs (He et al., Front Pharmacol 2022, PMID 36588717). Functional duration ~4 hours likely reflects tissue-level activity, not plasma half-life.

Pharmacokinetics — Active Dose Over Time

t½ = ~30 min plasma (functional tissue activity ~4 hours)

After 1 half-life (4h): 50% remainsAfter 2 half-lives (8h): 25% remainsAfter 3 half-lives (12h): 12.5% remains

At a 500mcg dose: 50% = 250mcg remaining after 4h. Recommended frequency: Daily.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

Side Effects

Very well-tolerated in research. Occasional mild nausea. No significant side effects reported in studies.

Contraindications

Pregnancy or breastfeeding (no reproductive safety data available)
Active cancer or history of cancer (BPC-157 promotes angiogenesis, which could theoretically support tumor growth)
Children and adolescents (no pediatric safety data)
Known hypersensitivity to BPC-157 or related peptides

Drug Interactions

Anticoagulants and antiplatelets — BPC-157 may modulate coagulation pathways; use caution with warfarin, heparin, or aspirin
NSAIDs — BPC-157 counteracts NSAID-induced GI damage, which may alter expected NSAID gastric side-effect profiles
Dopaminergic and adrenergic medications — BPC-157 interacts with dopamine and adrenergic systems, potentially modifying drug effects